<DOC>
	<DOCNO>NCT00642889</DOCNO>
	<brief_summary>To determine long-term safety efficacy dose range safinamide 50-200 mg/day , p.o. , compare placebo , add-on therapy patient early idiopathic Parkinson 's disease currently receive stable dose single dopamine ( DA ) agonist .</brief_summary>
	<brief_title>Safinamide Add-On Therapy Patients With Early Idiopathic Parkinson 's Disease Treated With Stable Dose Single Dopamine Agonist ( 12 Month Extension )</brief_title>
	<detailed_description>The study consist 12 month double-blind treatment . Patients continue take original treatment administer Study 015 ( safinamide 100 mg/day , safinamide 200 mg/day , placebo ) .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Dopamine</mesh_term>
	<mesh_term>Dopamine Agonists</mesh_term>
	<criteria>1 . The patient complete 24 week treatment Study 015 , patient discontinue prematurely , he/she return schedule efficacy evaluation Weeks 12 24 ( Visits 6 8 ) part Retrieved Dropout ( RDO ) population . 2 . The patient compliant take study medication Study 015 . 3 . The patient willing participate study sign approve Informed Consent form . 1 . The patient experience clinically significant adverse event would put patient risk participate study . 2 . The patient show clinically significant deterioration participation Study 015 . 3 . The patient discontinue Study 015 prematurely reason , return schedule efficacy evaluation Weeks 12 24 ( Visits 6 8 ) Study 015 .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2008</verification_date>
	<keyword>Parkinson 's disease</keyword>
</DOC>